Filing Details
- Accession Number:
- 0001127602-12-012003
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-03-28 13:00:00
- Reporting Period:
- 2012-03-26
- Filing Date:
- 2012-03-28
- Accepted Time:
- 2012-03-28 16:16:42
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
884731 | Ariad Pharmaceuticals Inc | ARIA | Biological Products, (No Disgnostic Substances) (2836) | 223106987 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1403174 | F Pierre Dodion | C/O Ariad Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge MA 02139 | Svp, Corp. Dev. & Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-03-26 | 25,000 | $5.49 | 97,232 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-03-26 | 25,000 | $16.50 | 72,232 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2012-03-26 | 25,000 | $0.00 | 25,000 | $5.49 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
50,000 | 2007-06-28 | 2017-06-28 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 0 | Indirect | Wife |
Footnotes
- Shares were acquired upon the exercise of outstanding stock options at $5.49 per share.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2011.